Literature DB >> 24710362

The price of good health.

.   

Abstract

Efficacious new drugs to treat hepatitis C virus infection offer the potential to halt this epidemic. But their exorbitant cost may prove prohibitive for most patients in need. Strong patient and government advocacy will be necessary to ensure that accessibility to treatments is a right, not a privilege.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24710362     DOI： 10.1038/nm.3538

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  1 in total

1.  Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Authors:  Andrew Hill; Saye Khoo; Joe Fortunak; Bryony Simmons; Nathan Ford
Journal:  Clin Infect Dis       Date:  2014-01-06       Impact factor: 9.079
  1 in total
  6 in total

1.  Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population.

Authors:  John Barron; Yiqiong Xie; Sze-Jung Wu; Jeff White; Joseph Singer; Bernard Tulsi; Alan Rosenberg
Journal:  Am Health Drug Benefits       Date:  2016-09

2.  Depsides: lichen metabolites active against hepatitis C virus.

Authors:  Thi Huyen Vu; Anne-Cécile Le Lamer; Claudia Lalli; Joël Boustie; Michel Samson; Françoise Lohézic-Le Dévéhat; Jacques Le Seyec
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.

Authors:  Ruthie B Birger; Thuy Le; Roger D Kouyos; Bryan T Grenfell; Timothy B Hallett
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

4.  Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

Authors:  Thierry Poynard; Olivier Deckmyn; Mona Munteanu; Yen Ngo; Fabienne Drane; Jean Marie Castille; Chantal Housset; Vlad Ratziu
Journal:  BMJ Open       Date:  2015-12-23       Impact factor: 2.692

5.  Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.

Authors:  Benjamin Heidrich; Steffen B Wiegand; Peter Buggisch; Holger Hinrichsen; Ralph Link; Bernd Möller; Klaus H W Böker; Gerlinde Teuber; Hartwig Klinker; Elmar Zehnter; Uwe Naumann; Heiner W Busch; Benjamin Maasoumy; Undine Baum; Svenja Hardtke; Michael P Manns; Heiner Wedemeyer; Jörg Petersen; Markus Cornberg
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

6.  A new paradigm evaluating cost per cure of HCV infection in the UK.

Authors:  Stephen T Barclay; Graham S Cooke; Elizabeth Holtham; Aline Gauthier; Jeremie Schwarzbard; Petar Atanasov; William L Irving
Journal:  Hepatol Med Policy       Date:  2016-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.